StocksMedium•27 October 2026•
1 min read
Vanda’s Tradipitant Reduces GLP-1 Induced Vomiting by 27% in Phase III Study
Key Facts
1Vanda Pharmaceuticals announced that tradipitant significantly reduced vomiting induced by GLP-1 therapy by 27% in a Phase III study.
2The study showed an 81% reduction in extreme vomiting (over 10 total episodes) compared to the placebo group.
Vanda Pharmaceuticals announced that its drug tradipitant significantly reduced vomiting induced by GLP-1 therapy by 27% in a Phase III study. According to a company statement on PR Newswire, the trial demonstrated an 81% reduction in extreme vomiting episodes—defined as over 10 total occurrences—compared to the placebo group.
The study addresses common gastrointestinal side effects associated with popular weight-loss and diabetes medications, representing a major market opportunity for the biotech firm. VNDA closed at $3.94 on October 26, 2026, having traded between a low of $3.92 and a high of $4.11 during that session.